GET DAILY SIGNALSLisata Therapeutics (LSTA) Prepares for Q3 2026 Results With Acquisition in Focus
Key Takeaways
- Lisata Therapeutics (LSTA), a clinical-stage biotechnology company, is preparing to report its third quarter of fiscal 2026 results, with the release expected in early-to-mid November.
- As a pre-revenue drug developer, Lisata's report will center on operating expenses, net loss per share, and its cash balance rather than product sales.
- Analyst coverage remains thin, but the company has beaten consensus earnings per share (EPS) estimates in seven of its last eight quarters.
- Management has flagged "substantial doubt" about the company's ability to continue as a going concern, putting its cash runway and pending acquisition by Kuva Labs at the center of investor attention.
- Clinical progress on certepetide, the lead tumor-penetrating peptide, will be closely watched, including data from the ASCEND pancreatic cancer trial and the BOLSTER bile duct cancer trial.
Why This Earnings Report Matters
For a company with essentially no product revenue, Lisata Therapeutics' quarterly report is less about the income statement and more about liquidity, spending discipline, and clinical momentum. The company develops certepetide, an investigational therapy designed to help anti-cancer drugs penetrate solid tumors more effectively. With a history of operating losses and a going concern warning in its latest filing, investors are watching whether Lisata can preserve capital while advancing its pipeline. The pending acquisition by Kuva Labs, announced in March 2026, adds another layer of significance, as the report could clarify the timing and conditions of the proposed deal. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Expect
Consensus figures for Lisata are sparse because of limited analyst coverage, but the available benchmarks offer a useful framework. In the year-ago third quarter, the company posted a net loss of $0.49 per share on essentially no revenue, while its most recent report (the second quarter of 2026) showed a loss of $0.32 per share. For full-year 2026, the single available consensus estimate stands at roughly $1.09 in losses per share. Investors will also monitor operating expenses, which have been trending lower, and the quarter-end cash balance, which was reported at about $10.4 million as of June 30, 2026.
Market Sentiment Around the Deal
Sentiment heading into Lisata's report is heavily influenced by the Kuva Labs merger agreement rather than the underlying financials alone. The proposed transaction offers $5.00 per share in cash plus a Contingent Value Right (CVR) worth up to $1.00 if a New Drug Application (NDA) is filed for certepetide within seven years. This structure means the stock may trade more on deal certainty and clinical milestones than on quarterly losses. Key risk factors include the potential for the tender offer timeline to slip, the company's limited cash runway if the deal fails to close, and uncertainty around final trial data for certepetide.
Looking Ahead: Key Things to Monitor
The most important variable to watch is the status of the Kuva Labs acquisition. Completion is not guaranteed, and investors will look for updates on the tender offer, expense reimbursements, and any conditions tied to the CVR. If the deal stalls, Lisata's ability to fund operations with roughly $10 million in cash becomes a central concern.
On the clinical front, the ASCEND trial in pancreatic cancer has shown encouraging preliminary signals of improved progression-free survival (PFS), while the BOLSTER trial in bile duct cancer showed no clear benefit. Final ASCEND data and any plans for later-stage studies will shape the pipeline's perceived value.
Finally, watch spending trends. Research and development (R&D) costs have fallen sharply following trial completions, and any commentary on partnership efforts or capital-raising plans will matter as the company navigates a pivotal period for its future.
Using AI Tools for Biotech Research
I often turn to Tickeron’s AI Screener when evaluating clinical-stage companies like this one. It lets me quickly filter biotech names by fundamentals, technical patterns, and recent performance to put the numbers in broader context. The tool has been helpful for spotting comparable opportunities without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for LSTA turns positive, indicating new upward trend
LSTA saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In 85 of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LSTA's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where LSTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for LSTA just turned positive on October 26, 2026. Looking at past instances where LSTA's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where LSTA advanced for three days, in 189 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
LSTA moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LSTA crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LSTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
LSTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LSTA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.299) is normal, around the industry mean (2.904). P/E Ratio (-0.605) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (131.579) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. LSTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LSTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement